2134020
Cooperative Agreement
Overview
Grant Description
SBIR Phase II: Innovative Platform for Low Volume Blood Coagulation Analysis - The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project addresses the problem of blood clotting and associated bleeding risks in neonatal and pediatric patients as well as vulnerable adult patients. Existing systems put these patients at further risk because they cannot operate with low volumes of blood, and because they are less reliable owing to the requirement for test sample contact.
Using only a single drop of blood, the proposed non-contact technology platform enables safe and reliable assessment of blood clotting for all patients and provides an opportunity for development of newborn screening tests for coagulation abnormalities. This technology can reduce side effects for neonatal and pediatric patients by using 1/100th the sample volume required by technologies developed for adult healthcare and improve diagnostic response time for critical care providers by more than 3x. This technology could decrease the cost of blood coagulation analysis by over 30%, thus allowing for patients in the United States to save $1.1 billion annually.
This Small Business Innovation Research (SBIR) Phase II project develops an innovative technology for non-contact blood coagulation analysis that integrates photo-optical and viscoelastic measurements in a single drop of blood. The basis of the technology is to levitate a small sample in a host fluid (air) by the acoustic radiation force and measure its physical properties under deformation during levitation. Due to its non-contact feature and low sample volume requirement, this technology can rapidly (<10 minutes) and reliably assess bleeding/thrombotic risks and is sensitive to temporal changes in shear viscosity and elasticity during blood clotting and fibrinolysis.
The goal of this project is to develop and test a system for fast, reliable, and easy-to-use drop-of-blood coagulation analysis under sterile conditions. This goal will be achieved by meeting four objectives: 1) develop the module for automatic sample deployment from standard blood collection tubes; 2) implement environmental control and sample containment ("acoustic cartridge"); 3) assemble prototype devices and develop the control software with improved workflow and a user-friendly interface; and 4) assess prototype reliability, standardize it for coagulation measurements, and conduct initial clinical testing.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Using only a single drop of blood, the proposed non-contact technology platform enables safe and reliable assessment of blood clotting for all patients and provides an opportunity for development of newborn screening tests for coagulation abnormalities. This technology can reduce side effects for neonatal and pediatric patients by using 1/100th the sample volume required by technologies developed for adult healthcare and improve diagnostic response time for critical care providers by more than 3x. This technology could decrease the cost of blood coagulation analysis by over 30%, thus allowing for patients in the United States to save $1.1 billion annually.
This Small Business Innovation Research (SBIR) Phase II project develops an innovative technology for non-contact blood coagulation analysis that integrates photo-optical and viscoelastic measurements in a single drop of blood. The basis of the technology is to levitate a small sample in a host fluid (air) by the acoustic radiation force and measure its physical properties under deformation during levitation. Due to its non-contact feature and low sample volume requirement, this technology can rapidly (<10 minutes) and reliably assess bleeding/thrombotic risks and is sensitive to temporal changes in shear viscosity and elasticity during blood clotting and fibrinolysis.
The goal of this project is to develop and test a system for fast, reliable, and easy-to-use drop-of-blood coagulation analysis under sterile conditions. This goal will be achieved by meeting four objectives: 1) develop the module for automatic sample deployment from standard blood collection tubes; 2) implement environmental control and sample containment ("acoustic cartridge"); 3) assemble prototype devices and develop the control software with improved workflow and a user-friendly interface; and 4) assess prototype reliability, standardize it for coagulation measurements, and conduct initial clinical testing.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Awardee
Grant Program (CFDA)
Awarding Agency
Place of Performance
New Orleans,
Louisiana
70118-5956
United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Levisonics was awarded
Cooperative Agreement 2134020
worth $998,857
from Directorate for Technology, Innovation and Partnerships in March 2022 with work to be completed primarily in New Orleans Louisiana United States.
The grant
has a duration of 2 years and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase II
Title
SBIR Phase II:Innovative Platform for Low Volume Blood Coagulation Analysis
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project addresses the problem of blood clotting and associated bleeding risks in neonatal and pediatric patients as well as vulnerable adult patients. Existing systems put these patients at further risk because they cannot operate with low volumes of blood, and because they are less reliable owing to the requirement for test sample contact. Using only a single drop of blood, the proposed non-contact technology platform enables safe and reliable assessment of blood clotting for all patients and provides an opportunity for development of newborn screening tests for coagulation abnormalities. This technology can reduce side effects for neonatal and pediatric patients by using 1/100th the sample volume required by technologies developed for adult healthcare and improve diagnostic response time for critical care providers by more than 3x. This technology could decrease the cost of blood coagulation analysis by over 30%, thus allowing for patients in the United States to save $1.1 billion annually.This Small Business Innovation Research (SBIR) Phase II project develops an innovative technology for non-contact blood coagulation analysis that integrates photo-optical and viscoelastic measurements in a single drop of blood. The basis of the technology is to levitate a small sample in a host fluid (air) by the acoustic radiation force and measure its physical properties under deformation during levitation. Due to its non-contact feature and low sample volume requirement, this technology can rapidly ( less than 10 minutes) and reliably assess bleeding/thrombotic risks and is sensitive to temporal changes in shear viscosity and elasticity during blood clotting and fibrinolysis. The goal of this project is to develop and test a system for fast, reliable, and easy-to-use drop-of-blood coagulation analysis under sterile conditions. This goal will be achieved by meeting four objectives: 1) develop the module for automatic sample deployment from standard blood collection tubes; 2) implement environmental control and sample containment (“acoustic cartridge”); 3) assemble prototype devices and develop the control software with improved workflow and a user-friendly interface; and 4) assess prototype reliability, standardize it for coagulation measurements, and conduct initial clinical testing.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BM
Solicitation Number
NSF 21-565
Status
(Complete)
Last Modified 4/5/22
Period of Performance
3/1/22
Start Date
2/29/24
End Date
Funding Split
$998.9K
Federal Obligation
$0.0
Non-Federal Obligation
$998.9K
Total Obligated
Activity Timeline
Transaction History
Modifications to 2134020
Additional Detail
Award ID FAIN
2134020
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
490707 DIVISION OF INDUSTRIAL INNOVATION
Awardee UEI
GFC8EGJU6VZ5
Awardee CAGE
7VR81
Performance District
01
Senators
Bill Cassidy
John Kennedy
John Kennedy
Representative
Steve Scalise
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $998,857 | 100% |
Modified: 4/5/22